MAb

Difficult-to-Express Proteins: Resolving Bioprocessing Challenges with a Scalable Perfusion Bioreactor

Continuous Bioprocessing

Difficult-to-Express Proteins: Resolving Bioprocessing Challenges with a Scalable Perfusion Bioreactor Difficult-to-Express Proteins: Resolving Bioprocessing Challenges with a Scalable Perfusion Bioreactor

+1

byScott Waniger, Emily Wozniakand 1 more

May 19, 2017

The Industry’s Hesitation to Adopt Continuous Bioprocessing: Recommendations for Deciding What, Where, and When to Implement

Continuous Bioprocessing

The Industry’s Hesitation to Adopt Continuous Bioprocessing: Recommendations for Deciding What, Where, and When to Implement The Industry’s Hesitation to Adopt Continuous Bioprocessing: Recommendations for Deciding What, Where, and When to Implement

Apr 17, 2017

Conditional/Inducible Gene-Expression Mouse Models Using Advanced Gene Editing

Process Development

Conditional/Inducible Gene-Expression Mouse Models Using Advanced Gene Editing Conditional/Inducible Gene-Expression Mouse Models Using Advanced Gene Editing

byNeeraja Parameswaran, Lanna Coxand 3 more

Mar 20, 2017

Buffers in Biologics Manufacturing

Buffers in Biologics Manufacturing Buffers in Biologics Manufacturing

byAngela Linderholm, Steven M. Chamowand 2 more

Feb 13, 2017

Special Report: A Strategy for Cost-Effective Capture Using Agarose-Based Protein A Resins

Sponsored Content

Special Report: A Strategy for Cost-Effective Capture Using Agarose-Based Protein A Resins Special Report: A Strategy for Cost-Effective Capture Using Agarose-Based Protein A Resins

byHans J. Johansson

Oct 27, 2016

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1 Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1

bySimran J. Kaur, Darryl Sampeyand 3 more

Oct 14, 2016

Addressing the Challenges of Developing Biopharmaceutical Drugs

Addressing the Challenges of Developing Biopharmaceutical Drugs

Addressing the Challenges of Developing Biopharmaceutical Drugs

byStefan Schlack

Standardized Economic Cost Modeling for Next-Generation MAb Production

Standardized Economic Cost Modeling for Next-Generation MAb Production

Standardized Economic Cost Modeling for Next-Generation MAb Production

+3

byDavid Pollard, Mark Browerand 3 more

Quality By Design for Monoclonal Antibodies, Part 2: Process Design Space and Control Strategies

Quality By Design for Monoclonal Antibodies, Part 2: Process Design Space and Control Strategies

Quality By Design for Monoclonal Antibodies, Part 2: Process Design Space and Control Strategies

+1

byBrendan Cooney, Susan Dana Jonesand 1 more

Performance Qualification of a Single-Use, Stirred-Tank Bioreactor with CHO-S Cell Culture

Performance Qualification of a Single-Use, Stirred-Tank Bioreactor with CHO-S Cell Culture

Performance Qualification of a Single-Use, Stirred-Tank Bioreactor with CHO-S Cell Culture

+1

byBojan Isailovic, Byron Reesand 1 more

Optimizing Continuous Monoclonal Antibody Polishing By Using Coupled Unit Operations

Sponsored Content

Optimizing Continuous Monoclonal Antibody Polishing By Using Coupled Unit Operations

Optimizing Continuous Monoclonal Antibody Polishing By Using Coupled Unit Operations

+1

byXhorxhi Gjoka, Mark Schofieldand 1 more

Critical Factors for Fill–Finish Manufacturing of Biologics

Critical Factors for Fill–Finish Manufacturing of Biologics

Critical Factors for Fill–Finish Manufacturing of Biologics

byDon Paul Kovarcik

Fucosylation of a Therapeutic Antibody: Effects on Antibody-Dependent, Cell-Mediated Cytotoxicity (ADCC) Potency and Efficacy

Fucosylation of a Therapeutic Antibody: Effects on Antibody-Dependent, Cell-Mediated Cytotoxicity (ADCC) Potency and Efficacy

Fucosylation of a Therapeutic Antibody: Effects on Antibody-Dependent, Cell-Mediated Cytotoxicity (ADCC) Potency and Efficacy

+4

byDavid T. Ho, John F. Parkand 4 more

Rapid Formulation Development for Monoclonal Antibodies

Rapid Formulation Development for Monoclonal Antibodies

Rapid Formulation Development for Monoclonal Antibodies

+1

byJichao Kang, Xi Linand 1 more

A Single-Use Process for Production of Recombinant Human Follicle-Stimulating Hormone

Expression Platforms

A Single-Use Process for Production of Recombinant Human Follicle-Stimulating Hormone

A Single-Use Process for Production of Recombinant Human Follicle-Stimulating Hormone

+5

byShady Tamman, Mina Hanyand 5 more

Alkyl Mono- and Diglucosides: Highly Effective, Nonionic Surfactant Replacements for Polysorbates in Biotherapeutics — a Review

Alkyl Mono- and Diglucosides: Highly Effective, Nonionic Surfactant Replacements for Polysorbates in Biotherapeutics — a Review

Alkyl Mono- and Diglucosides: Highly Effective, Nonionic Surfactant Replacements for Polysorbates in Biotherapeutics — a Review

byEdward Maggio

Responding to an FDA Form 483: A Five-Step Approach

Responding to an FDA Form 483: A Five-Step Approach

Responding to an FDA Form 483: A Five-Step Approach

byTaylor Burtis

Automated Purification of Native and Recombinant Proteins Using Multidimensional Chromatography

Automated Purification of Native and Recombinant Proteins Using Multidimensional Chromatography

Automated Purification of Native and Recombinant Proteins Using Multidimensional Chromatography

+2

byJeff Habel, Phillip Elmsand 2 more

Development, Qualification, and Application of a Bioreactor Scale-Down Process: Modeling Large-Scale Microcarrier Perfusion Cell Culture

Expression Platforms

Development, Qualification, and Application of a Bioreactor Scale-Down Process: Modeling Large-Scale Microcarrier Perfusion Cell Culture

Development, Qualification, and Application of a Bioreactor Scale-Down Process: Modeling Large-Scale Microcarrier Perfusion Cell Culture

+5

byCaroline DiCesare, Marcella Yuand 5 more

Sponsored Content

Ask the Expert: FOLDTEC Refolding of Biopharmaceuticals A Case Study of Recombinant Thrombin

Ask the Expert: FOLDTEC Refolding of Biopharmaceuticals A Case Study of Recombinant Thrombin

Decision-Support Tools for Monoclonal Antibody and Cell Therapy Bioprocessing: Current Landscape and Development Opportunities

Decision-Support Tools for Monoclonal Antibody and Cell Therapy Bioprocessing: Current Landscape and Development Opportunities

Decision-Support Tools for Monoclonal Antibody and Cell Therapy Bioprocessing: Current Landscape and Development Opportunities

+6

byRahul Rekhi, James A. Smithand 6 more

Comprehensive Hands-On Training for Biopharmaceutical Manufacturing: BTEC’s Program to Deliver Training to FDA Investigators

Comprehensive Hands-On Training for Biopharmaceutical Manufacturing: BTEC’s Program to Deliver Training to FDA Investigators

Comprehensive Hands-On Training for Biopharmaceutical Manufacturing: BTEC’s Program to Deliver Training to FDA Investigators

byGary Gilleskie, Patty Brown

Compatibility Assessment of a Model Monoclonal Antibody Formulation in Glass and Blow–Fill–Seal Plastic Vials

Compatibility Assessment of a Model Monoclonal Antibody Formulation in Glass and Blow–Fill–Seal Plastic Vials July 2015

Compatibility Assessment of a Model Monoclonal Antibody Formulation in Glass and Blow–Fill–Seal Plastic Vials July 2015

+1

byDipesh Shah, Gregory Bleckand 1 more

Anion-Exchange Chromatographic Clarification: Bringing Simplification, Robustness, and Savings to MAb Purification

Anion-Exchange Chromatographic Clarification: Bringing Simplification, Robustness, and Savings to MAb Purification

Anion-Exchange Chromatographic Clarification: Bringing Simplification, Robustness, and Savings to MAb Purification

+2

byAngelines A. Castro-Forero, Zona Jokondoand 2 more

An Industrial Platform Solution for Antibody Fragment Purification

Separation/Purification

An Industrial Platform Solution for Antibody Fragment Purification

An Industrial Platform Solution for Antibody Fragment Purification

byJonathan Royce

Improved Fluorescent Labeling Efficiency of N-Linked, High-Mannose Oligosaccharides: Using 8-Aminopyrene-1,3,6-Trisulfonic Acid (APTS) for Analysis

Improved Fluorescent Labeling Efficiency of N-Linked, High-Mannose Oligosaccharides: Using 8-Aminopyrene-1,3,6-Trisulfonic Acid (APTS) for Analysis of Glycoproteins

Improved Fluorescent Labeling Efficiency of N-Linked, High-Mannose Oligosaccharides: Using 8-Aminopyrene-1,3,6-Trisulfonic Acid (APTS) for Analysis of Glycoproteins

+4

byYuling Zhang, Philip Campbelland 4 more

The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics

The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics

The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics

+2

byThomas Palm, Erinc Sahinand 2 more

Characterization of Postcapture Impurity Removal Across an Adsorptive Depth Filter

Characterization of Postcapture Impurity Removal Across an Adsorptive Depth Filter

Characterization of Postcapture Impurity Removal Across an Adsorptive Depth Filter

+7

byJohn Schreffler, Matthew Bailleyand 7 more

A Multidisciplinary Approach to Manufacturing Biotherapeutics

A Multidisciplinary Approach to Manufacturing Biotherapeutics

A Multidisciplinary Approach to Manufacturing Biotherapeutics

+3

byJeffrey Breit, Brandon Downeyand 3 more

Affinity Capture of F(ab’)<sub>2</sub> Fragments: Using Twin-Column Countercurrent Chromatography

Affinity Capture of F(ab’)2 Fragments: Using Twin-Column Countercurrent Chromatography

Affinity Capture of F(ab’)2 Fragments: Using Twin-Column Countercurrent Chromatography

+4

byNicole Ulmer, Thomas Muller-Spathand 4 more

Protein A Intermediate Wash Strategies

Protein A Intermediate Wash Strategies

Protein A Intermediate Wash Strategies

+1

byMelissa Holstein, Kristen Cotoniand 1 more

Immunoglobulin Fc-Fusion Proteins Part 2: Therapeutic Uses and Clinical Development

Immunoglobulin Fc-Fusion Proteins Part 2: Therapeutic Uses and Clinical Development

Immunoglobulin Fc-Fusion Proteins Part 2: Therapeutic Uses and Clinical Development

byAngela Linderholm, Steven M. Chamow

Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture

Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture

Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture

byAngela Linderholm, Steven M. Chamow

Antibody Drug Conjugates: The State of the Art

Antibody Drug Conjugates: The State of the Art

byUwe Gottschalk

Bioprocessing Challenges of Antibody–Drug Conjugates

Bioprocessing Challenges of Antibody–Drug Conjugates

Bioprocessing Challenges of Antibody–Drug Conjugates

byRonald A. Rader